Press Release – Page 2 – Amplyx

FDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Multiple Invasive Fungal and Mold Infections

11/15/2016/by admin

Amplyx Pharmaceuticals Initiates Dosing in Phase 1 Clinical Trial of APX001, a Novel Antifungal Product Candidate for Treatment of Life-Threatening Infections

09/12/2016/by admin

Amplyx Pharmaceuticals Appoints Paul C. Grint, M.D., to Board of Directors

05/24/2016/by admin

Amplyx Pharmaceuticals Announces Qualified Infectious Disease Product Designation for APX001 in Three Life-threatening Fungal Infections

06/14/2016/by admin

Amplyx Pharmaceuticals Expands Management Team and Increases Its Series B Financing to $49.2 Million

02/09/2016/by admin

Amplyx Pharmaceuticals Secures $40.5 Million in Series B Financing

11/11/2015/by admin